The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression
Open accessAbstract
Recent neuroimaging and postmortem studies have demonstrated abnormalities in glutamatergic transmission in major depression. Glutamate NMDA (N-methyl-d-aspartate) receptors are one of the major mediators of excitatory neurotransmission in the central nervous system. At synaptic sites, NMDA receptors are linked with postsynaptic density protein-95 (PSD-95) that plays a key role in mediating trafficking, clustering, and downstream signaling events, following receptor activation. In this study, we examined the expression of NMDA receptor subunits NR1, NR2A, and NR2B as well as PSD-95 in the anterior prefrontal cortex (PFC) using Western blot method. Cortical samples were obtained from age, gender and postmortem interval matched depressed and psychiatrically healthy controls. The results revealed that there was a reduced expression of the NMDA receptor subunits NR2A (-54%) and NR2B (-48%), and PSD-95 protein level (-40%) in the PFC of depressed subjects relative to controls, with no change in the NR1 subunit. The alterations in NMDA receptor subunits, especially the NR2A and NR2B, as well as PSD-95 suggest an abnormality in the NMDA receptor signaling in the PFC in major depression. Our findings in conjunction with recent clinical, cellular, and neuroimaging studies further implicate the involvement of glutamate neurotransmission in the pathophysiology of depression. This study provides additional evidence that NMDA receptor complex is a target for discovery of novel antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence in support of a reduction of synapse number is provided by reports of decreased levels of synaptic signaling proteins in MDD patients, including decreased levels of glutamate receptor subtypes, presynaptic neurotransmitter vesicle-associated proteins, and postsynaptic structural and functional proteins in the dlPFC, the hippocampus, and other forebrain structures (16–19).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Postmortem studies have demonstrated that patients with depression and related mental illnesses have lower BDNF and/or TRKB mRNA levels (75–77), reduced cortical neuron size (75, 78, 79), lower synaptic protein levels (80), decreased mTOR signaling (81), and fewer dendritic spines/synapses (82, 83) in the PFC.”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [80]
In the citing paper
“Protein expression levels of the NMDA subunits NR2A/NR2B and PSD95 are also reduced in PFC of MDD patients 210”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [210]
In the citing paper
“It is interesting to note that the expression and function of mTORC1 signaling proteins is reduced in postmortem PFC of depressed subjects, which could contribute to decreased synthesis of synaptic proteins in PFC of depressed subjects50,51.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535
Domain Interaction Between NMDA Receptor Subunits and the Postsynaptic Density Protein PSD-95
Kornau, H., Schenker, L. T., Kennedy, M. B., & Seeburg, P. H. (1995) · Science · doi:10.1126/science.7569905 · Cited by 1,916
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Self-citationAnterior prefrontal cortex: insights into function from anatomy and neuroimaging
Ramnani, N., & Owen, A. M. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1343 · Cited by 1,170
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 422
Gong, W., Zhou, Y., Gong, W., & Qin, X. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112533 · Cited by 25
Lee, C. J., Fang, Y.-P., Chu, M.-C., Chung, Y.-J., Chi, H., Tang, C., So, E. C., Lin, H.-C., & Lin, H.-C. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.064 · Cited by 26
Chen, T., Zhang, B., Li, G., Chen, L., & Chen, L. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.028 · Cited by 25
Liu, Y., Zou, G.-J., Tu, B.-X., Hu, Z., Luo, C., Cui, Y., Xu, Y., Li, F., Dai, R., Bi, F., et al. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00201-4 · Cited by 25
Antidepressant-like effect of guanosine involves activation of AMPA receptor and BDNF/TrkB signaling
da Rosa, P. B., Bettio, L. E. B., Neis, V. B., Moretti, M., Kaufmann, F. N., Tavares, M. K., Werle, I., Dalsenter, Y. D. O., Platt, N., Rosado, A. F., et al. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09779-6 · Cited by 26
Abdel‐Bakky, M. S., Amin, E., Faris, T. M., & Abdellatif, A. A. H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12479 · Cited by 26
The antidepressant-like effect of alarin is related to TrkB-mTOR signaling and synaptic plasticity
Zhuang, F., Li, M., Gao, X., Wang, Y., Wang, D., Ma, X., Ma, T., & Gu, S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.057 · Cited by 27
Lei, Y., Yaroslavsky, I., & Tejani‐Butt, S. M. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.10.010 · Cited by 25
Halaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 27
Differential effects of NMDA receptor antagonism on spine density
Ruddy, R. M., Chen, Y., Milenkovic, M., & Ramsey, A. J. (2014) · Synapse · doi:10.1002/syn.21784 · Cited by 23
Suicidal Ideation during Antidepressant Treatment
Perroud, N. A. (2011) · CNS Drugs · doi:10.2165/11589420-000000000-00000 · Cited by 23
Wei, S., Womer, F. Y., Geng, H., Jiang, X., Zhou, Q., Chang, M., Zhou, Y., Tang, Y., & Wang, F. (2017) · Scientific Reports · doi:10.1038/srep44316 · Cited by 24
Bansal, Y., Codeluppi-Arrowsmith, S. A., & Banasr, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126357 · Cited by 25
Zhu, M., Chen, Y., Zheng, J., Zhao, P., Xia, M., Tang, Y., & Wang, F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03265-y · Cited by 28
Abdoulaye, I. A., Wu, S.-S., Chibaatar, E., Yu, D., Le, K., Cao, X., & Guo, Y. (2021) · Neural Plasticity · doi:10.1155/2021/6635084 · Cited by 23
Weigand, A., Gärtner, M., Scheidegger, M., Wyss, P. O., Henning, A., Seifritz, E., Stippl, A., Herrera-Meléndez, A. L., Bajbouj, M., Aust, S., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac049 · Cited by 22
How could N-Methyl-D-Aspartate Receptor Antagonists Lead to Excitation Instead of Inhibition?
Su, T., Lu, Y., Geng, Y., Lü, W., & Chen, Y. (2018) · Brain Science Advances · doi:10.26599/bsa.2018.2018.9050009 · Cited by 26
Réus, G. Z., Stringari, R. B., Rezin, G. T., Fraga, D. B., Daufenbach, J. F., Scaini, G., Benedet, J., Rochi, N., Streck, E. L., & Quevedo, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0718-2 · Cited by 23
Engler-Chiurazzi, E. B. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1360242 · Cited by 27
Dysregulation of complement system in neuropsychiatric disorders: A mini review
Sierra, D. P., Tripathi, A., & Pillai, A. (2022) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2022.100056 · Cited by 24
Cai, M., Park, H. R., & Yang, E. J. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02663-4 · Cited by 23
McWhirt, J., Sathyanesan, M., Sampath, D., & Newton, S. S. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100169 · Cited by 23
Wang, D., Li, B., Wu, Y., & Li, B. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00695-3 · Cited by 21
Shah, A. J., Mir, R. H., Mohi-ud-din, R., Pottoo, F. H., Masoodi, M. H., & Bhat, Z. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210426115234 · Cited by 21
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Samojedny, S., Czechowska, E., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911423 · Cited by 22
Effects of Venlafaxine and Escitalopram Treatments on NMDA Receptors in the Rat Depression Model
Yılmaz, N., Demirdaş, A., Yilmaz, M., Sütçü, R., Kırbaş, A., Cüre, M. C., & Eren, İ. (2011) · The Journal of Membrane Biology · doi:10.1007/s00232-011-9385-3 · Cited by 21
mTOR signaling in the neuropathophysiology of depression: current evidence
Rodrigues, A. L. S., Réus, G. Z., & Quevedo, J. (2015) · Journal of Receptor Ligand and Channel Research · doi:10.2147/jrlcr.s70351 · Cited by 21
Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders
Costi, S., Dam, N. T. V., & Murrough, J. W. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0052-3 · Cited by 21
Piva, A., Caffino, L., Mottarlini, F., Pintori, N., Díaz, F. C., Fumagalli, F., & Chiamulera, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02352-7 · Cited by 21
Réus, G. Z., Matias, B. I., Maciel, A. L., Abelaira, H. M., Ignácio, Z. M., de Moura, A. B., Matos, D., Danielski, L. G., Petronilho, F. C., Carvalho, A. F., et al. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.04.021 · Cited by 21
Du Jardin, K. G., Müller, H. K., Sanchez, C., Wegener, G., & Elfving, B. (2017) · Synapse · doi:10.1002/syn.21940 · Cited by 20
da Silva, R. H., Pedro, L. C., Manosso, L. M., Gonçalves, C. L., & Réus, G. Z. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.050 · Cited by 22
Zeng, J., Wang, Z., Zhang, X., Zhao, A., Qi, H., Jiang, Y., Cai, D., & Zeng, N. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156927 · Cited by 21
Yang, Y., Chen, C., Zhan, J., Liu, Q.-S., Liu, Y., Jiang, S.-Z., & Wei, B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.765664 · Cited by 20
Antidepressant-Like Effect and Mechanism of Ginsenoside Rd on Rodent Models of Depression
Li, Y., Wang, M.-L., Zhang, B., Fan, X., Tang, Q., Yu, X., Li, L.-N., Fan, A.-R., Chang, H.-S., & Zhang, L.-Z. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s351421 · Cited by 20
Kennedy, S. H., Young, A. H., & Blier, P. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.048 · Cited by 20
Cholewinski, T., Pereira, D., Moerland, M., & Jacobs, G. E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211036814 · Cited by 20
Liu, X., Tang, S., Liu, S.-M., Zeng, J., Chen, Z., Liu, C.-H., Mu, R.-H., Yuan, D.-H., Zhao, J., Hong, H., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105922 · Cited by 19
Ketamine, benzoate, and sarcosine for treating depression
Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 20
Moretti, M., Werle, I., da Rosa, P. B., Neis, V. B., Platt, N., Souza, S. V. D. S., & Rodrigues, A. L. S. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172800 · Cited by 19
Saez, E., Erkoreka, L., Moreno-Calle, T., Berjano, B., González-Pinto, A. M., Basterreche, N., & Arrúe, A. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i7.884 · Cited by 20
Rajkumar, R., & Dawe, G. S. (2018) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.04.001 · Cited by 20
Chen, D., Qi, X., Zhuang, R., Cao, J., Xu, Y., Huang, X., & Li, Y. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.11.032 · Cited by 19
Lee, C. J., Chen, Y., Wu, H.-F., Chung, Y.-J., Lee, Y., Li, C., & Lin, H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.015 · Cited by 20
How do antidepressants influence the BOLD signal in the developing brain?
Harris, J. J., & Reynell, C. (2016) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2016.12.003 · Cited by 20
Therapeutic Implications of microRNAs in Depressive Disorders: A Review
Hassan, M., Amir, A., Shahzadi, S., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113530 · Cited by 21
Effects of High Levels of Copper on the Depression-Related Memory Disorders
Liu, X., Lin, C., Wang, S., Yu, X., Jia, Y., & Chen, J. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac222 · Cited by 21
Mutant disrupted‐in‐schizophrenia 1 in astrocytes: Focus on glutamate metabolism
Abazyan, S., Yang, E. J., Abazyan, B. N., Xia, M., Yang, C., Rojas, C. J., Slusher, B. S., Sattler, R., & Pletnikov, M. V. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23459 · Cited by 17
Allopregnanolone increases mature excitatory synapses along dendrites via protein kinase A signaling
Shimizu, H., Ishizuka, Y., Yamazaki, H., & Shirao, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.079 · Cited by 18
Camargo, A., Dalmagro, A. P., Wolin, I. A. V., Siteneski, A., Zeni, A. L. B., & Rodrigues, A. L. S. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110371 · Cited by 17
A review of new insights into existing major depressive disorder biomarkers
Rimti, F. H., Shahbaz, R., Bhatt, K., & Xiang, A. J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18909 · Cited by 21
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
Altered synaptic homeostasis: a key factor in the pathophysiology of depression
Wang, B., He, T., Qiu, G., Li, C., Xue, S., Zheng, Y., Wang, T., Xia, Y., Yao, L., Yan, J., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01369-y · Cited by 19
Yang, B., Qin, J., Nie, Y., & Chen, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6876 · Cited by 17
Marcin, L. R., Warrier, J., Thangathirupathy, S., Shi, J., Karageorge, G. N., Pearce, B. C., Ng, A., Park, H., Kempson, J., Li, J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00080 · Cited by 18
Tsang, V. W. K., Young, D., During, M. J., & Birch, N. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091050 · Cited by 18
Kouba, B. R., Torrá, A. C. N. C., Camargo, A., & Rodrigues, A. L. S. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01115-0 · Cited by 16
The role of NMDA receptors in bipolar disorder: A systematic review
Weiss, F., Caruso, V., Rosa, U. D., Beatino, M. F., Barbuti, M., Nicoletti, F., & Perugi, G. (2023) · Bipolar Disorders · doi:10.1111/bdi.13335 · Cited by 16
Wang, Y., Zhao, M., Xie, C., Li, L., Lin, L., Li, Q., Li, L., Chen, F., Yang, X., Yang, J., et al. (2024) · Foods · doi:10.3390/foods13132154 · Cited by 17
Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders
Onisiforou, A., Michael, A., Apostolakis, M., Mammadov, E., Mitka, A., Kalatta, M. A., Koumas, M., Georgiou, A. N., Chatzittofis, A., Panayiotou, G., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.09.008 · Cited by 16
Camargo, A., Dalmagro, A. P., Zeni, A. L. B., & Rodrigues, A. L. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.186 · Cited by 18
PET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 17
Mizera, J., Kazek, G., Niedzielska, E., & Pomierny-Chamioło, L. (2021) · The FASEB Journal · doi:10.1096/fj.202002691r · Cited by 21
Possible antidepressant mechanism of acupuncture: targeting neuroplasticity
Xu, N., He, Y., Wei, Y.-N., Bai, L., & Wang, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1512073 · Cited by 20
Chen, B., Xu, J., Chen, S., Mou, T., Wang, Y., Wang, H., Zhang, Z., Ren, F., Wang, Z., Jin, K., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.031 · Cited by 15
Flynn, L. T., & Gao, W. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02235-4 · Cited by 16
Brandley, E. T., Kirkland, A. E., Baron, M. I., Baraniuk, J. N., & Holton, K. F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.926688 · Cited by 15
Fan, Z., Qian, Y., Lu, Q., Wang, Y., Chang, S., & Yang, L. (2018) · Brain and Behavior · doi:10.1002/brb3.914 · Cited by 15
Hasegawa, S., Yoshimi, A., Mouri, A., Uchida, Y., Hida, H., Mishina, M., Yamada, K., Ozaki, N., Nabeshima, T., & Noda, Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.020 · Cited by 15
Targeting the dysfunction of glutamate receptors for the development of novel antidepressants
Xia, C., He, J., Du, L., Yan, Y., Lian, W., Xu, J., & Zhang, W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107875 · Cited by 15
Glutamate-Based Drug Discovery for Novel Antidepressants
Pałucha-Poniewiera, A., & Pilc, A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1213234 · Cited by 17
Suicide Is a Confounder in Postmortem Studies on Depression
Zhao, J., Lucassen, P. J., & Swaab, D. F. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.015 · Cited by 16
Deciphering the Metabolome under Stress: Insights from Rodent Models
Papageorgiou, M. P., Theodoridou, D., Nußbaumer, M., Syrrou, M., & Filiou, M. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230713094843 · Cited by 15
Parikh, S. V., Voort, J. L. V., Yocum, A. K., Achtyes, E. D., Goes, F. S., Nykamp, L. J., Singh, B., Lopez-Vives, D., Sera, C. E., Maixner, D. F., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.033 · Cited by 15
Gandy, H. M., Hollis, F., Hernandez, C. M., & McQuail, J. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1306496 · Cited by 13
The Pathophysiological Underpinnings of Gamma-Band Alterations in Psychiatric Disorders
Palmisano, A., Pandit, S., Smeralda, C. L., Demchenko, I., Rossi, S., Battelli, L., Rivolta, D., Bhat, V., & Santarnecchi, E. (2024) · Life · doi:10.3390/life14050578 · Cited by 17
Wada, M., Nakajima, S., Honda, S., Takano, M., Taniguchi, K., Homma, S., Ueda, R., Tobari, Y., Mimura, Y., Fujii, S., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03186-2 · Cited by 15
The keys to improving depression outcomes
Rizvi, S. J., & Kennedy, S. H. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.002 · Cited by 14
Banerjee, P., Donello, J., Hare, B. D., & Duman, R. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112706 · Cited by 13
McNamara, R. K., Asch, R., Schurdak, J. D., & Lindquist, D. M. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.10.003 · Cited by 14
Kim, Y., Lee, J. S., & Joo, Y. H. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0838-2 · Cited by 14
Raab‐Graham, K. F., Workman, E. R., Namjoshi, S. V., & Niere, F. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.020 · Cited by 13
Gisabella, B., Babu, J., Valeri, J., Rexrode, L., & Pantazopoulos, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.646678 · Cited by 16
Bansal, Y., Fee, C., Misquitta, K. A., Codeluppi-Arrowsmith, S. A., Sibille, E. L., Berman, R., Coric, V., Sanacora, G., & Banasr, M. (2023) · Complex Psychiatry · doi:10.1159/000529534 · Cited by 12
Potential biomarkers of emotional stress induced neurodegeneration
Zafar, T. (2020) · eNeurologicalSci · doi:10.1016/j.ensci.2020.100292 · Cited by 14
Gregoire, M. J., Sirtori, R., Donatelli, L., Potts, E. M., Collins, A., Zamor, D., Katenka, N., & Fallini, C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406998121 · Cited by 12
Molecular Mechanisms of Depression
Varidaki, A., Mohammad, H., & Coffey, E. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00005-4 · Cited by 13
Kaut, O., Sharma, A., Schmitt, I., Hurlemann, R., & Wüllner, U. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.05.030 · Cited by 12
Zhu, W., Yang, F., Cai, X., Zhang, W., Zhang, J., Cai, M., Li, X., Xiang, J. Y., & Cai, D. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01845-x · Cited by 15
GRIN2B gene expression is increased in the anterior cingulate cortex in major depression
Brown, S. J., Brown, A. M., Purves-Tyson, T. D., Huang, X., Weickert, C. S., & Newell, K. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.017 · Cited by 12
Kántor, S., Lanigan, M., Giggins, L., Lione, L. A., Magomedova, L., de Lannoy, I., Upton, N., & Duxon, M. S. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114473 · Cited by 13
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 14
Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
NR2B overexpression leads to the enhancement of specific protein phosphorylation in the brain
Li, C., Zhang, N., Hu, Y., & Wang, H. (2014) · Brain Research · doi:10.1016/j.brainres.2014.08.005 · Cited by 11
Andreou, D., Söderman, E., Axelsson, T., Sedvall, G. C., Terenius, L. Y., Agartz, I., & Jönsson, E. G. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.023 · Cited by 11
Kinase-mediated signaling cascades in mood disorders and antidepressant treatment
Yuan, L., Wauson, E., & Đurić, V. (2016) · Journal of Neurogenetics · doi:10.1080/01677063.2016.1245303 · Cited by 12
Pubertal LPS treatment selectively alters PSD-95 expression in male CD-1 mice
Kolmogorova, D., & Ismail, N. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.07.025 · Cited by 11
Verrusio, W., Renzi, A., Cecchetti, F., Gaj, F., Coi, M., Ripani, M., & Cacciafesta, M. (2018) · The journal of nutrition health & aging · doi:10.1007/s12603-018-1044-2 · Cited by 12
Zhu, H., Wang, B., Wang, T., Shao, J., Chen, H., Zhang, C., Xu, L., Li, J., Wang, M., Xu, D., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.124137 · Cited by 10
Eid, R. S., Lieblich, S. E., Wong, S. J., & Galea, L. A. M. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100199 · Cited by 10
Metadata
- Authors
- Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B.
- Affiliations
- University of Mississippi Medical Center (US)
- Corresponding author
- Karolewicz, Beata
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 33
- Issue
- 1
- Pages
- 70-75
- ISSN
- 0278-5846 (ISSN-L)
- PMC
- PMC2655629
- OpenAlex
- W2054535395
- Cited by
- 421
- References
- 46
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 29 · 2023: 28 · 2022: 31 · 2021: 34 · 2020: 34 · 2019: 25 · 2018: 25 · 2017: 14 · 2016: 27 · 2015: 28 · 2014: 24 · 2013: 21 · 2012: 15
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p20rr017701-10)
- National Institute of Mental Health (R01MH067996, MH67996)
- National Center for Research Resources (P20-RR-017701, RR 17701)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, NMDA receptor, NR2A, NR2B, NR1 subunit, PSD-95, prefrontal cortex, glutamatergic neurotransmission, postmortem brain, antidepressant targets, glutamatergic dysfunction
- MeSH terms
- Disks Large Homolog 4 Protein, Adult, Carrier Proteins, Major Depressive Disorder, Female, Humans, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review